Framycetin
From Wikipedia, the free encyclopedia
Framycetin
|
|
Systematic (IUPAC) name | |
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl) -6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R) -4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl) -4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy -5-(hydroxymethyl)oxolan-2-yl]oxy -3-hydroxycyclohexyl]oxyoxane-3,4-diol |
|
Identifiers | |
CAS number | ? |
ATC code | R01 |
PubChem | |
Chemical data | |
Formula | C23H46N6O13 |
Mol. mass | 614.644 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | oral, topical |
Framycetin is an antibiotic of the aminoglycoside class similar to neomycin. Like neomycin, it has poor systemic absorption. It is used in topical preparations for infections of the skin, nose, ears, and eyes, often in combination with other antibacterial drugs and corticosteroids. It can also be used for gastrointestinal infections.
Framycetin is commonly sold as Soframycin and Sofra-Tulle.
|
|